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Background
In Tetralogy of Fallot (TOF), surgical repair is undertaken
in childhood but standard repair techniques result in pul-
monary regurgitation (PR). With time this induces right
ventricular (RV) dilation and dysfunction and is associ-
ated with an increased risk of sudden death. Although pul-
monary valve replacement (PVR) has been shown to
improve symptoms, appropriate timing for this procedure
continues to be debated. This study aims to evaluate the
safety, feasibility and diagnostic potential of high dose
dobutamine stress magnetic resonance imaging (DS-MR)
in the assessment of right ventricular contractile reserve in
post repair TOF with significant PR.
Methods
26 patients with repaired TOF and PR referred for cardiac
MRI were prospectively recruited. In addition to morpho-
logical assessment ventricular volumes (2D cine MRI)
pulmonary artery and aortic flows (phase contrast) were
obtained at baseline and during dobutamine infusion:
Stage 1 DS-MR 10 mcg/kg/min an Stage 2 DS-MR 20 mcg/
kg/min. Data comparison was performed using the stu-
dent t-test (p < 0.05).
Results
Of the 26 patients, DS-MR imaging data is incomplete, in
one patient due to claustrophobia and in the second due
to failure of VECG triggering secondarily to frequent ven-
tricular ectopics. Twenty-four patients completed stage 1
DS-MR. Five patients could not progress to Stage 2, due to
either minor dobutamine side effects (nausea or head-
ache) or achievement of maximum predicted heart rate.
Nineteen patients went on to complete stage 2 stress with
no severe adverse side effects. The heart rate (cardiac
index) increased from 66 ± 6 bpm (2.9 ± 0.4 l/min/m2) at 
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Change in end diastolic volume for the left and right ventricle at baseline and with dobuta ine stress at 10 and 20 mcg/kg/minFigur 1
Change in end diastolic volume for the left and right 
ventricle at baseline and with dobutamine stress at 
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Baseline n = 26 (mean ± SD) Dobutamine 10 n = 24 (mean ± SD) Dobutamine 20 n = 19 (mean ± SD)
Heart Rate bmp 66.5 ± 9.2 91 ± 18.8 117.5 ± 14.4
Systolic BP mmhg 125 ± 14 144 ± 18 155 ± 22
Diastolic BP mmhg 70 ± 6 76 ± 7 77 ± 6
LV EDV ml/m2 77.4 ± 14.9 67.6 ± 16.4 54.66 ± 12.8
LV ESV ml/m2 32.9 ± 10.3 23.9 ± 8.9 16.3 ± 5.62
LV SV ml/m2 43.7 ± 7.4 43.82 ± 12.1 38.3 ± 9.2
LV CO l/mon/m2 2.8 ± 0.45 3.97 ± 0.9 4.5 ± 1.0
LV EF % 57.8 ± 7.3 64.7 ± 10.7 70.4 ± 6.3
RV EDV ml/m2 127.6 ± 25.93 123.8 ± 26.9 110.8 ± 25.3
RV ESV ml/m2 58.4 ± 17.6 50.0 ± 20.0 45.4 ± 14.9
RV SV ml/m2 69.2 ± 11.9 73.7 ± 14.6 65.4 ± 14.4
RV CO l/min/m2 4.5 ± 1 6.82 ± 1.85 7.79 ± 1.7
RV EF % 55 ± 6.8 60.4 ± 9.43 59.8 ± 7.7
PR (%) 43 ± 15.4 44.9 ± 11.2 43.6 ± 12.1
BP: blood pressure, LV: left ventricle, RV: right ventricle, EDV: end diastolic volume, ESV: end systolic volume, SV: stroke volume, CO: cardiac 
output, EF: ejection fractions, PR: pulmonary regurgitant fraction.
Change in end systolic volume for the left and right ventricle at baseline and wi h dobuta ine stress a 10 and 20 mcg/kg/minFigur 2
Change in end systolic volume for the left and right 
ventricle at baseline and with dobutamine stress at 
10 and 20 mcg/kg/min.
Sub-groups defined by change in right ventricular end systolic volume (RV-ESV)Figur 3
Sub-groups defined by change in right ventricular 
end systolic volume (RV-ESV). Group 1-patients with no 
change or an increase in RV-ESV with dobutamine 20 mcg. 
Group 2-patients with a decrease in RV-ESV with dob-
utamine 20 mcg.Page 2 of 3
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baseline to 91 ± 18 bpm (3.9 ± 0.9 l/min/m2) at Stage 1
and 117 ± 14 bpm (4.5 ± 1 l/min/m2) at Stage 2 (p <
0.01), volumetric changes are detailed in Table 1. Signifi-
cant reduction in left ventricular (LV) end diastolic (EDV)
and end systolic volumes (ESV) is seen at dobutamine 10
and 20 (p < 0.01). In the right ventricle (RV) there is a less
marked reduction in volumes at 10 whilst at 20 mcg dob-
utamine there is no significant change in end systolic vol-
ume in a sub-group (P = 0.63) Figures 1, 2 and 3.
Conclusion
Our data shows that high dose dobutamine stress MR is
safe and well tolerated in patients with corrected TOF with
PR. In the LV there is a clear reduction in volume at each
level of dobutamine, whereas the RV showed less
response at 10 mcg and in a sub-group failed to reduce
RV-ESV at stage 2 DS-MR. The change in RV-ESV under
stress may become a discriminative parameter in TOF
patients being assessed for pulmonary valve replacement.Page 3 of 3
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